Last week, Dr. Ross Camidge from the University of Colorado joined me on a webinar entitled "One Size Does Not Fit All" in which he discussed the early work on ALK rearrangements and the novel agent PF-02341066 (now known as crizotinib) in particular, and the new era of molecularly defined practice of oncology in particular. This story has been widely considered to be among the most important in the field of lung cancer over the last few years, and Dr. Camidge did not disappoint.
Not only did many of the participants in the live program write comments here expressing their positive feedback on the great energy and overall quality of the program, but both our transcriber and the editor of our podcasts independently commented to me that they thought it was a terrific podcast and that they learned a lot (and they don't have a special, vested interest in lung cancer issues).
Here's the audio and video podcast links, as well as the transcript and the figures from the webinar:
Finally, I'd like to personalize this a bit, because one of the people who was mentioned in the podcast, Andy Hill, has also been featured in the local news in both Seattle (link to news report here) and Denver (link here) as a remarkable example of the promise of molecular oncology. He's also been a dedicated and extremely helpful supporter of GRACE in terms of both financial support and participating in our recent programs and some meetings as we work on the future directions for our organization. So I'd like to dedicate the program to Andy and hope he continues to redefine the great success of this work in how well he does.
Speaking of which, we could really benefit from your support for these programs. This webinar wasn't from a grant but rather from your contributions. I hope you find these activities helpful and will support them. I'd also encourage people to tell others, provide the link, if you know of anyone else who might benefit from learning the material in our educational programs. We'd hate to think of the Andy Hills out there who may miss a chance for a very helpful treatment because they simply didn't know such a possibility might exist. And unfortunately, many oncologists are still not aware of these developments: the field is simply moving too quickly.
Comments or questions? We'd love to get your feedback.